Table 2.
Grade 3 and 4 toxicities occurring in at least 5% of patients or involving hepatotoxicity during chemoradiotherapy and maintenance cycles 1–6 (as one group)
| Toxicity Type | Reporting Period |
|||
|---|---|---|---|---|
| Chemoradiotherapy (N = 106a) |
Maintenance (N = 90) |
|||
| N | % | N | % | |
| Hemoglobin | 1 | 0.9 | 22 | 24.4 |
| Leukocytes (total WBC) | 8 | 7.5 | 46 | 51.1 |
| Lymphopenia | 20 | 18.9 | 27 | 30 |
| Neutrophils/granulocytes (ANC/AGC) | 12 | 11.3 | 57 | 63.3 |
| Platelets | 15 | 14.2 | 47 | 52.2 |
| Nausea | 1 | 0.9 | 5 | 5.6 |
| ALT, SGPT (serum glutamic pyruvic transaminase) | 0 | 0 | 2 | 2.2 |
| AST, SGOT(serum glutamic oxaloacetic transaminase) | 0 | 0 | 3 | 3.3 |
| Bilirubin (hyperbilirubinemia) | 0 | 0 | 1 | 1.1 |
aTwo patients did not begin protocol therapy and are therefore excluded from toxicity calculations.